<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830750</url>
  </required_header>
  <id_info>
    <org_study_id>35821</org_study_id>
    <nct_id>NCT02830750</nct_id>
  </id_info>
  <brief_title>Low Fluoroscopy Afib Ablation Registry</brief_title>
  <official_title>A Multi Center Registry of Low- Fluoroscopy Atrial Fibrillation Ablation Using Electroanatomic Mapping Carto</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beacon Medical Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allegheny Health Network Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective data collection of patients undergoing Atrial Fibrillation Ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinicians who have experience using low dose fluoroscopy including use of Carto Mapping
      system will consent patients to allow data collection and a 12 month f/up visit to track
      adverse events. Clinicians will follow a protocol which will be similar to their standard of
      care for ablations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Atrial Fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>Determine Atrial Fibrillation burden at 12 month visit by reviewing monitoring systems that capture this data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopic Usage</measure>
    <time_frame>post operative</time_frame>
    <description>To determine total amount of radiation used at each procedure by estimation of mGy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have persistant or paroxysmal atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient meets accepted AHA/ACC/HRS guideline indications for catheter ablation of
             paroxysmal or persistent AF

          -  First or subsequent ablation procedures may be included

          -  Age 18-75

        Exclusion Criteria:

          -  Known venous malformations or implanted instrumentation (IVC filter)

          -  Known PV stenosis

          -  Unable to provide consent

          -  H/O mechanical mitral valve replacement (unable to rely on EA mapping only)

          -  Documented left atrial thrombus

          -  Prior ASD repair Pregnancy

          -  NYHA &gt;=3

          -  EF less than 35%

          -  CHF within 90 daysRecent MI or coronary revascularization within 90 days

          -  NOTE: H/O implanted pacemaker or ICD with transvenous leads will NOT be an exclusion
             criteria, but we will track patients treated with pre-existing transvenous leads with
             the hypothesis that although fluoroscopy use will be higher in these patients
             compared to those without leads, but still lower than conventionally treated
             patients.

          -  Patients who are undergoing non- standard of care ablations ie, Cyro or FIRM
             ablations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Zei, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerri O'Riordan, BSN RN</last_name>
    <phone>650 7255597</phone>
    <email>gor@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beacon Medical Group</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toni Rihm</last_name>
      <phone>574-647-6584</phone>
    </contact>
    <investigator>
      <last_name>Ramon Mitra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 10, 2016</lastchanged_date>
  <firstreceived_date>June 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Paul Zei</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
